Silicon Drugs & Intermediates Profile
Key Indicators
- Authorised Capital ₹ 3.30 Cr
as on 06-07-2024
- Paid Up Capital ₹ 2.63 Cr
as on 06-07-2024
- Company Age 13 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.50 Cr
as on 06-07-2024
- Revenue -83.09%
(FY 2021)
- Profit 98.96%
(FY 2021)
- Ebitda 99.62%
(FY 2021)
- Net Worth -3.33%
(FY 2021)
- Total Assets -16.37%
(FY 2021)
About Silicon Drugs & Intermediates
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.30 Cr and a paid-up capital of Rs 2.63 Cr.
The company currently has active open charges totaling ₹7.50 Cr.
Gade Reddy, Addanki Prasad, and Siva Vuyyuru serve as directors at the Company.
- CIN/LLPIN
U24100TG2011PTC072926
- Company No.
072926
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Feb 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Silicon Drugs & Intermediates?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Addanki Prasad  | Director | 25-Feb-2011 | Current |
| Gade Reddy | Director | 25-Feb-2011 | Current |
| Siva Vuyyuru | Director | 25-Feb-2011 | Current |
Financial Performance and Corporate Structure Insights of Silicon Drugs & Intermediates.
Silicon Drugs & Intermediates Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 83.09% decrease. The company also saw a substantial improvement in profitability, with a 98.96% increase in profit. The company's net worth dipped by a decrease of 3.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Silicon Drugs & Intermediates?
In 2021, Silicon Drugs & Intermediates had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vvr Organics Private Limited
Active 20 years 9 monthsGade Reddy and Addanki Prasad are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 16 May 2011 | ₹7.50 Cr | Open |
How Many Employees Work at Silicon Drugs & Intermediates?
Silicon Drugs & Intermediates has a workforce of 7 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Silicon Drugs & Intermediates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Silicon Drugs & Intermediates's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
